March 2025. For 15 years, Delex Pharma has been a leading force in the Philippine healthcare sector, consistently delivering high-quality pharmaceutical products and building a reputation for excellence. With its impressive history, extensive product offerings, and visionary expansion strategies, DELEX is poised for unprecedented growth. The BNCM DELEX merger sets the foundation for the company’s long-term ambition to lead not only in the Philippines but across global markets.
Here’s a closer look at the BNCM DELEX growth plans, based on Delex Pharma's strengths and strategic roadmap designed to propel its success well into the future and drive innovation, growth, and market leadership in the healthcare sector.
15 Years of Robust Business Growth
Delex Pharma’s legacy is built on 15 years of sustained growth, ranking as the third-largest national player in the hospital channel market according to IQVIA. The company’s leadership team, with over three decades of experience in the healthcare sector, has played an integral role in driving this growth and positioning DELEX as a powerhouse within the industry. These milestones further strengthen the BNCM DELEX merger narrative.
Leadership That Drives Excellence
At the helm of DELEX is a group of seasoned leaders with extensive experience in both the pharmaceutical and medical industries. Their entrepreneurial acumen and expertise, honed through years of working with multinational healthcare giants, empower DELEX to continually adapt and thrive in a competitive market. This leadership ensures the company’s future success as they continue to execute on the BNCM DELEX growth plans.
Holder of Various FDA Business Licenses & Permits
From importing and distributing pharmaceutical products to running drugstores and medical devices, Delex Pharma is fully equipped to meet the regulatory standards that govern the diverse landscape of the Philippine healthcare industry. DELEX currently holds various licenses and permits issued by the Philippines Food and Drug Administration for (i) Importer/Wholesaler/Distributor of Drugs, (ii) Importer of Medical Devices, (iii) Food Wholesaler, (iv) Cosmetic Importer and Wholesaler, and (v) Drugstore Operator, including Online Order and Delivery.
Holder of 30 FDA-Approved Hospital Products
DELEX Pharma is committed to continuously expanding its product portfolio to meet the needs of both healthcare professionals and patients. With over 30 FDA-approved hospital products and numerous medical device products, DELEX is pushing the boundaries of innovation. The company’s recent launch of 11 new pharmaceutical products and strategic partnerships with multinational medical device firms further reflect the depth of the BNCM DELEX growth plans.
Expanding the Distribution Channels
With a network that already supplies nearly 700 hospitals nationwide and has established a foothold in over 900 Mercury Drug branches, DELEX is positioned for even greater reach. By building on its strong distribution network and forming strategic partnerships with healthcare providers, Delex Pharma aims to expand its footprint. These efforts are aligned with the long-term vision outlined in the BNCM DELEX merger roadmap to improve patient outcomes and deliver integrated healthcare solutions.
Expanding the Medical Device Business
The medical device market in the Philippines is experiencing rapid growth, and DELEX is well-positioned to capitalize on this opportunity. With a strategic alliance with leading international companies such as Amsino, Masimo, and Verathon, Delex Pharma aims to be a key player in the medical device sector. This initiative is central to the broader BNCM DELEX growth plans, reinforcing the company’s commitment to high-quality healthcare solutions.
Expanding the Pharmacy Stores
Building on the success of its first pharmacy branch opened in 2021, DELEX plans to expand its retail pharmacy business to 60 locations in the coming years. This expansion aligns with the broader BNCM DELEX merger strategy and comes at a time when the pharmacy market is poised for significant growth. With a smart location strategy near hospitals and high-traffic areas, Delex Pharma aims to generate strong sales while addressing community healthcare needs.
Expanding the Online Pharmacy Business
As the healthcare landscape becomes increasingly digital, DELEX is tapping into the rapidly growing ePharmacy market. Through its online platform, Delex Pharma offers a seamless 24/7 ordering and delivery service for a wide range of over-the-counter medicines, prescription drugs, and health products. These efforts support the broader vision of BNCM DELEX growth plans and allow the company to serve a larger, more digitally connected population.
Expand DELEX’s Training Programs and Global Networks
DELEX has proven its commitment to improving healthcare outcomes through educational initiatives such as the DELEX ICU Forum. What began as an in-person event has grown into a powerful online platform that has attracted nearly 200,000 healthcare professionals worldwide. This aligns with BNCM's strategy of becoming one of the most undervalued pharma stocks transforming into a thought leader in healthcare innovation.
Strategic Acquisition to Expand DELEX’s Product Portfolio
In 2022, Delex Pharma made a significant move to acquire JMN Brothers Pharma Limited, a company known for its expertise in women’s health and beauty. This acquisition, part of the BNCM DELEX merger, enables the company to expand its hospital product portfolio and tap into new market segments, further increasing its market share in the healthcare sector.
Commitment to Quality Through ISO Certification
Delex Pharma’s commitment to quality and operational excellence has been recognized globally. The company recently underwent and passed the ISO 9001:2015 re-certification, underscoring its dedication to meeting international quality standards. These recognitions add to BNCM's emerging reputation as one of the most undervalued pharma stocks with significant long-term value.
Strong Distribution and Warehouse Capabilities
With a robust infrastructure that includes a dedicated trade sales team and state-of-the-art SAP ERP systems, DELEX ensures efficient distribution and inventory management. This operational efficiency allows Delex Pharma to respond promptly to customer demands and maintain high levels of service across its entire distribution network.
Winner of Several Industry Awards
DELEX’s track record of success is reflected in the numerous accolades and awards the company has received. These include recognition as the “Diversity Company of the Year” and “SME Company of the Year” by the Asia CEO Awards, as well as individual honors for its leadership team. These awards solidify BNCM's transformation from a local player to a leader among the most undervalued pharma stocks in the region.
Asia’s Booming Pharmaceutical Market
With the Asian pharmaceutical market projected to reach US$304.8 billion by 2029, Delex Pharma is poised to play a key role in this rapidly growing industry. The company’s strategic positioning, along with the BNCM DELEX merger, gives it a competitive edge as the market continues to grow at a steady pace.
Name Change and Ticker Symbol
A formal application to rename BNCM to DELEX and update the ticker symbol will be applied from Q1 2025, aligning with the new direction of the merged company. This rebrand is a critical part of the BNCM DELEX merger, reflecting the company’s ambition to further solidify its presence in the global healthcare market and prepare for an exciting phase of expansion.
Regulation A Filing and SEC Approval
To support its future growth, DELEX Pharma plans to file for Regulation A with the SEC from March 2025, opening up new avenues for investment and funding. This filing plays a strategic role in executing the BNCM DELEX growth plans and achieving its long-term business objectives.
Uplist to DELEX OTCQB and NASDAQ
BNCM plans to take its corporate visibility to the next level by applying for an uplist to the OTCQB in 2025, with the ultimate goal of listing on the NASDAQ. This move will heighten BNCM and DELEX's visibility among global investors and further validate its position as one of the most undervalued pharma stocks in Asia.
DELEX Pharma: A Future of Growth and Innovation
With a proven track record of success, a visionary leadership team, and a strategic expansion plan that spans multiple facets of the healthcare industry, Delex Pharma is poised to become a dominant player in the global healthcare market. As BNCM and DELEX continue to innovate, expand, and strengthen their presence in key sectors, they remain on track to achieve ambitious goals and deliver value to stakeholders. The future of Delex Pharma looks brighter than ever, and investors have a unique opportunity to be part of this dynamic journey.
For more information, visit – https://bncm.us/
Stay updated on our latest news – https://bncm.us/news-videos/
Get in touch with us – https://bncm.us/get-in-touch/
Disclaimer:
The information presented in this article is for informational purposes only and does not constitute financial, investment, or business advice. DELEX future plans, projections, and growth strategies are subject to various risks and uncertainties, and actual results may differ significantly. Investors should conduct their own research and consult with a financial advisor before making any investment decisions. DELEX is not responsible for any financial or investment outcomes resulting from the use of this information.